Dravet Syndrome Market

Dravet syndrome, earlier known as severe myoclonic epilepsy of infancy (SMEI), is an epilepsy syndrome that develops in infancy or early childhood. It can include a spectrum of symptoms that range from mild to severe. Children suffering from Dravet syndrome show generalized (throughout the brain) or focal (confined to one are) convulsive seizures that begin before the age of one. These seizures involve half of the body and are often prolonged. However, subsequent seizures may shift to the other half of the body. The initial seizures are provoked by temperature changes such as getting out of the bath. In addition, these seizures are difficult to control but they can be reduced by the use of anticonvulsant drugs. For instance, the FDA has approved the use of the drug fenfluramine in kids aged 2 years and older with Dravet syndrome.

COVID-19 Impact Analysis

COVID-19 is an infectious disease that originated in the Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing a shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness significant growth in the future, owing to the demand for vaccines and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the acute respiratory distress syndrome market.

Top Impacting Factors

The dynamics of the Dravet syndrome market are all set to experience a positive shift due to the expected launch of different novel emerging therapies. These therapies include development of new drugs such as cannabidiol and stiripentol.

In addition, availability of favorable reimbursement policies both during the late and early stages of therapeutic product development is anticipated to have a positive impact on the growth of the global Dravet syndrome market.

Various other factors such as increase in government assistance in research and development and improvement in regulatory framework of the healthcare industry boost the market growth. With a better regulatory framework research activities related to Dravet syndrome do not have to face stringencies. In addition, rise in funding, and increase in acceptability of Dravet syndrome therapies is contributing toward the growth of the market.

Owing to the maturation of pipelines to include disease-modifying treatments, the Dravet syndrome market is expected to grow in seven major markets, including Canada, Germany, Italy, France, Japan, the UK and the U.S. Among these, the US exhibits the highest market size.

However, lack of awareness, side effects of therapeutic agents & drugs, and poor healthcare system in developing economies hinder the growth of the market.

Market Trends

The Dravet syndrome market size is expected to increase at a significant CAGR during the forecast period. U.S. accounts for the highest market size.

Reducing seizure frequency is the primary aim in managing Dravet syndrome patients. First-line management of the syndrome hence involves either clobazam or valproic acid. PTC Therapeutics, Inc., and Zogenix, Inc. have their therapies for this in pipelines.

In recent years, due to novel upcoming drugs for treatment, Dravet syndrome has gained attention. In February 2018, the FDA designated Zogenix, Inc. for its breakthrough therapy product known as ZXOO8. This drug is indicated for the treatment of the complications related to Dravet syndrome.

Various pharmaceutical companies such as OPKO Health, Inc. and Insys Therapeutics, Inc. are putting continuous efforts to control the complications related to Dravet syndrome. These companies are further focusing on manufacturing novel drugs for the syndrome.

Key Benefits of the Report

• This study presents the analytical depiction of the Dravet syndrome industry along with the current trends and future estimations to determine the imminent investment pockets.
• The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the market share.
• The current market is quantitatively analyzed to highlight the market growth scenario.
• Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
• The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in the coming years.

Questions answered in the Dravet syndrome Report

• Which are the leading players active in the Dravet syndrome market?
• How is each segment of the market expected to grow during the forecast period?
• What are the adoption trends for the Dravet syndrome market in emerging economies and established economies across the world?
• What are the current trends that will influence the market in the next few years?
• What are the driving factors, restraints, and opportunities of the market?
• What future projections would help in taking further strategic steps?
• What is "Dravet syndrome"?
• What is the "Dravet syndrome" market prediction in the future?
• What are the current trends and predicted trends?

 Dravet Syndrome Market Report Highlights